Abstract 1216
Background
The MF07-01 trial is a multicenter randomized study comparing locoregional treatment (LRT) followed by systemic therapy (ST) with ST alone in de novo stage IV breast cancer (BC) patients. The aim of this study is to evaluate the importance of LRT in patients who lived at least 5 years after the diagnosis of de novo Stage IV BC.
Methods
At initial diagnosis, patients were randomized 1:1 to either the LRT or ST group. All the patients were given ST either immediately after randomization or after surgical resection of the intact primary tumor. Continuous and categorical variable differences between LRT and ST groups were analyzed using t-test and Chi-square test, respectively. Overall survival (OS) and 5-year survival rates were compared using Kaplan-Meier log-rank tests. Univariate and multivariate Cox models were used to estimate hazard ratios.
Results
During 124 months of follow-up, 26% of patients in LRT group and 11% of patients in ST group remained alive. Median survival was 46 months for LRT (n = 134) and 35.5 months for ST (n = 132) [HR:0.65, 95%CI;0.49-0.85, p = 0.002]. Solitary bone metastasis patients’ median survival was 14.5 months longer in the LRT group compared with the ST group [HR:0.53, 95%CI; 0.29-0.98, p = 0.04]; 22% of solitary bone metastasis patients in the LRT group and 5% in the ST group were alive. Regarding the patients who lived at least 5 years since randomization, LRT (p = 0.004), hormone receptor positivity (p = 0.007), hormonotherapy (p = 0.0001), bisphosphonates usage (p = 0.02), T2 tumor (p = 0.0008) and 2 or more organ metastases (p = 0.007) were associated with OS in univariate analysis, and in a multivariate Cox proportional model with a significant baseline and clinical characteristics, LRT [OR = 1.75, p = 0.05)], bisphosphonates usage [OR = 1.93, p = 0.05), T2 tumor [OR = 3.5, p = 0.003), and 2 or more organ metastases [OR = 0.48, p = 0.03] were found to be significantly related with OS.
Conclusions
In the current analysis, patients at the diagnosis of de novo stage IV BC who underwent LRT followed by ST had a 75% higher chance to live at least 5 years compared with the patients who received only ST. Longer follow-up of the study discloses that LRT should be presented to the patient when discussing treatment options.
Clinical trial identification
NCT00557986.
Editorial acknowledgement
Legal entity responsible for the study
Turkish Federation of Breast Diseases Societies.
Funding
Turkish Federation of Breast Diseases Societies.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1911 - PIK3CA Alterations in Metastatic Breast Cancer (mBC)
Presenter: Joan Albanell
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
4351 - Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: an exploratory analysis of the PADA-1 trial
Presenter: Francois-Clement Bidard
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
3596 - Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial
Presenter: Yen-Shen Lu
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
5019 - Efficacy and Safety of First China-Manufactured Trastuzumab Biosimilar HLX02 for Metastatic Breast Cancer: A Phase 3 Trial
Presenter: Binghe Xu
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
2713 - Leuprorelin (LEUP) combined with Letrozole (LET) with/without Everolimus (EVE) in Ovarian suppressed premenopausal women with hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC): Primary analysis of LEO Trial (NCT02344550)
Presenter: Jaeho Jeong
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
Poster Discussion - Breast cancer, metastatic - Invited Discussant 306PD and 307PD
Presenter: Aleix Prat
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Slides
Webcast
1589 - Patient-reported outcomes of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer from the YoungPearl phase ll trial (KCSG-BR 15-10, NCT02592746)
Presenter: Soohyeon Lee
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
Poster Discussion - Breast cancer, metastatic - Invited Discussant LBA24 and 308PD
Presenter: Alexandru Eniu
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Slides
Webcast
Poster Discussion - Breast cancer, metastatic - Invited Discussant 309PD and 310PD
Presenter: Sherko Kümmel
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Slides
Webcast
1076 - MONARCHplus: A Phase 3 Trial of Abemaciclib plus Nonsteroidal Aromatase Inhibitor (NSAI) or Fulvestrant (F) for Women with HR+/HER2- Advanced Breast Cancer (ABC)
Presenter: Zefei Jiang
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract